These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 19191085)

  • 1. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
    Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
    Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
    [No Abstract]   [Full Text] [Related]  

  • 2. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 3. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
    MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
    [No Abstract]   [Full Text] [Related]  

  • 4. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
    Sharma A; Baliga V;
    J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ARBs for cardiovascular and renal protection in high-risk patients.
    Aalbers J
    Cardiovasc J Afr; 2011; 22(4):224. PubMed ID: 21881697
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].
    Middeke M
    Dtsch Med Wochenschr; 2012 Nov; 137(48):2498. PubMed ID: 23168983
    [No Abstract]   [Full Text] [Related]  

  • 7. [New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].
    Nilsson PM
    Lakartidningen; 2008 May 7-13; 105(19):1382-4. PubMed ID: 18574975
    [No Abstract]   [Full Text] [Related]  

  • 8. New data on ONTARGET: more confusion?
    Escobar C; Echarri R; Barrios V
    J Clin Hypertens (Greenwich); 2010 Mar; 12(3):199. PubMed ID: 20433538
    [No Abstract]   [Full Text] [Related]  

  • 9. Is therapy of people with chronic kidney disease ONTARGET?
    Mann JF; Tobe S; Teo KK; Yusuf S
    Nephrol Dial Transplant; 2010 Jan; 25(1):42-4. PubMed ID: 19854846
    [No Abstract]   [Full Text] [Related]  

  • 10. Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.
    Yu LT; Zhu J; Tan HQ; Wang GG; Teo KK; Liu LS
    Chin Med J (Engl); 2011 Jun; 124(12):1763-8. PubMed ID: 21740829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
    Burnier M; Waeber B; Hess O; Lüscher T
    Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New clinical concepts after the ONTARGET trial.
    Ruilope LM; Segura J; Zamorano JL
    Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteinuria: Is the ONTARGET renal substudy actually off target?
    Ruggenenti P; Remuzzi G
    Nat Rev Nephrol; 2009 Aug; 5(8):436-7. PubMed ID: 19639016
    [No Abstract]   [Full Text] [Related]  

  • 17. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ONTARGET should not be over interpreted.
    Abutaleb N
    Nephrol Dial Transplant; 2010 Jan; 25(1):44-7. PubMed ID: 19934088
    [No Abstract]   [Full Text] [Related]  

  • 19. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.